To include your compound in the COVID-19 Resource Center, submit it here.

Fa(c)ts about metabolic syndrome

Numerous groups are developing products to treat obesity, but few are developing products to treat metabolic syndrome, which is characterized by accumulation of excessive abdominal fat, diabetes, hyperlipidemia, and atherosclerosis. However, new research suggests that modulation of a single peripheral enzyme, 11-beta hydroxysteroid dehydrogenase type 1 (11B-HSD-1), could be

Read the full 498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE